Tempest Therapeutics, Inc. (TPST)
| Market Cap | 18.51M -27.1% |
| Revenue (ttm) | n/a |
| Net Income | -43.10M |
| EPS | -7.16 |
| Shares Out | 14.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,278 |
| Open | 1.250 |
| Previous Close | 1.230 |
| Day's Range | 1.230 - 1.300 |
| 52-Week Range | 1.220 - 12.230 |
| Beta | -1.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About TPST
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr... [Read more]
Financial Performance
Financial StatementsNews
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake R...
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therap...
Tempest Therapeutics Proxy statement: Proxy filing
Tempest Therapeutics filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)
Tempest Therapeutics Earnings release: Q1 2026
Tempest Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Tempest Therapeutics Quarterly report: Q1 2026
Tempest Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest Therapeutics Slides: Corporate presentation
Tempest Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest Therapeutics provides update on development of TPST-2003
Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed...
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to suppor...
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Pha...
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on April 2, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
06:07 EDT Tempest Therapeutics (TPST) files to sell 2.78M shares of common stock for holders
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
18:00 EDT Tempest Therapeutics (TPST) files to sell 8.27M shares of common stock for holders
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing...
Tempest Therapeutics Annual report: Q4 2025
Tempest Therapeutics has published its Q4 2025 annual report on March 30, 2026.
Tempest Therapeutics Earnings release: Q4 2025
Tempest Therapeutics released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Tempest Therapeutics Registration statement: Registration filing
Tempest Therapeutics filed a registration statement on March 30, 2026, providing details about a securities offering with the SEC.
Tempest Therapeutics Announces Up To $6 Million Private Placement
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell ther...
Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study
Tempest Therapeutics (TPST) announced the selection of Cincinnati Children’s Applied Gene and Cell Therapy Center as the lead contract development and manufacturing partner to conduct the formal techn...
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned t...
Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003
Tempest Therapeutics (TPST) announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy. TPST-2003 is being developed in China by ...
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and sma...